A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 23\~116 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma.

Trial Details

NCT ID
NCT06083207
Phase
PHASE1 / PHASE2
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • IBI3003
Locations (sample)
  • Wollongong, New South Wales, Australia|-34.424,150.89345
  • Heidelberg, Victoria, Australia|-37.75,145.06667
  • Melbourne, Victoria, Australia|-37.814,144.96332
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Nanning, Guangxi, China|22.81667,108.31667

Key Eligibility Criteria

  • Subjects in Parts 1(dose escalation) \& 2 (dose expansion) must satisfy all of the following criteria to be enrolled into the study:
  • Age ≥18 years. For Part 1, age ≥18 years and ≤75 years.
  • Documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria. Multiple myeloma is defined as clonal bone marrow plasma ce…
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →